Damora Therapeutics, Inc. Ordinary Shares
DMRA
26 hedge funds and large institutions have $17.8M invested in Damora Therapeutics, Inc. Ordinary Shares in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 1 closing their positions.
800% more call options, than puts
Call options by funds: $18K | Put options by funds: $2K
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
74% more capital invested
Capital invested by funds: $10.2M → $17.8M (+$7.61M)
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
18% more funds holding
Funds holding: 22 → 26 (+4)
0.01% more ownership
Funds ownership: 1.39% → 1.4% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.1K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$53.4K |
| 3 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$46.8K |
| 4 |
TCOT
Trust Company of Toledo
Holland,
Ohio
|
+$25.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$10.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$19K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8.65K |
| 3 |
Two Sigma Investments
New York
|
-$6.12K |
| 4 |
ACP
Arcus Capital Partners
Atlanta,
Georgia
|
-$557 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACP
26
Arcus Capital Partners
Atlanta,
Georgia
| – | -$557 | -19 | Closed |
|
27
Simplex Trading
Chicago,
Illinois
| – | +$633 | +12 | New |
|
DMRA Hedge Fund Activity: Q1 2023 in Review
26 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q1 2023, worth a combined $17.8M — up 74% from $10.2M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new DMRA positions and 1 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $56.1K. The largest seller was Two Sigma Advisers, cutting an estimated $19K.
- 26 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q1 2023, up from 22 in Q4 2022.
- Funds reported $17.8M of Damora Therapeutics, Inc. Ordinary Shares stock for Q1 2023, up 74% quarter-over-quarter.
- 5 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q1 2023 and 1 closed out, a net change of +4 holders.
- The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q1 2023 was Vanguard Group, an estimated $56.1K added.
- The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q1 2023 was Two Sigma Advisers, an estimated $19K sold.
Based on aggregated 13F filings for Q1 2023.